The pharmaceutical and biopharmaceutical industry is engaged in an unprecedented search for products to potentially treat, cure or prevent COVID-19. AgencyIQ has reviewed ClinicalTrials.gov, company announcements and media reports to provide a detailed landscape of the COVID-19 development pipeline. As of April 15, 2020, there are more than 150 candidates in various stages of testing to assess their potential effects against COVID-19.
Some of these potential therapies have already been approved for other purposes and are now being assessed for their potential to treat COVID-19, while others are being repurposed from other late-stage development pipelines. Others are still in the very early stages of development and have not yet been tested in humans.